News
UTHR
577.58
-0.17%
-0.96
United Therapeutics CFO James Edgemond disposes of common shares worth $5,747,755.31
PUBT · 1d ago
United Therapeutics CEO Martine Rothblatt disposes common shares worth $5,378,572.62
PUBT · 2d ago
Weekly Report: what happened at UTHR last week (0406-0410)?
Weekly Report · 3d ago
A Look At United Therapeutics (UTHR) Valuation After RMAT Win And Tyvaso Phase 3 Success
Simply Wall St · 3d ago
United Therapeutics CEO Martine Rothblatt disposes of shares worth $5.45 million
Reuters · 5d ago
United Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 5d ago
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $519
Benzinga · 5d ago
Is It Too Late To Consider United Therapeutics (UTHR) After A 106% One-Year Surge?
Simply Wall St · 5d ago
Nike downgraded, IBM initiated: Wall Street’s top analyst calls
TipRanks · 5d ago
United Therapeutics price target raised to $519 from $471 at Morgan Stanley
TipRanks · 5d ago
Morgan Stanley Remains a Hold on United Therapeutics (UTHR)
TipRanks · 5d ago
UNITED THERAPEUTICS CORP <UTHR.O>: RAYMOND JAMES INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $700
Reuters · 5d ago
United Therapeutics initiated with an Outperform at Raymond James
TipRanks · 6d ago
BKMC, XPO, WWD, UTHR: Large Outflows Detected at ETF
NASDAQ · 6d ago
The Bull Case For United Therapeutics (UTHR) Could Change Following RMAT Status And TETON-1 Success - Learn Why
Simply Wall St · 04/08 22:25
United Therapeutics's MiroliverELAP Gets FDA RMAT Designation For Acute Liver Failure Treatment
NASDAQ · 04/08 12:27
United Therapeutics announces FDA granted RMAT designation to miroliverELAP
TipRanks · 04/08 11:16
United Therapeutics wins FDA RMAT designation for miroliverELAP in acute liver failure
Reuters · 04/08 11:00
UNITED THERAPEUTICS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR MIROLIVERELAP® FOR TREATMENT OF ACUTE LIVER FAILURE
Reuters · 04/08 11:00
United Therapeutics CFO James Edgemond disposes of shares worth $4,963,865.64
Reuters · 04/07 20:36
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.